Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : $424.0 million
Deal Type : Licensing Agreement
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
Details : Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutations
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : $424.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Partnership
Pfizer Partners with Quotient to Leverage Genetics Against Heart, Renal Diseases
Details : The companies will analyze somatic mutations in diseased patient tissue to inform the discovery and development of potentially transformative therapies for cardiovascular and renal diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Bitterroot and Biotheus Collaborate to Develop Bispecific Proteins in Cardio-Immunology
Details : This collaboration will focus on discovering and developing medicines that may offer new hope for patients suffering from atherosclerosis and other life-threatening cardiovascular conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Phlox Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will integrate Solid Biosciences’ vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics to develop novel precision genetic medicines f...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Phlox Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : LX2021
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Sarepta Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
Details : In connection with this investment, the companies will explore the development of novel gene therapy candidates, including LX2021 and LX2022 for a range of cardiovascular diseases.
Product Name : LX2021
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : LX2021
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Sarepta Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Riparian Pharmaceuticals Announces Agreements with Pfizer for Novel Cardiovascular Programs
Details : Under the agreement, Pfizer will support Riparian’s efforts to discover further drug targets leading to vasoprotection and will have an option on such targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Bain Capital Life Sciences
Deal Size : $300.0 million
Deal Type : Financing
Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital
Details : The investment will support the advancement of Cardurion’s pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program, and enable the Company to scale its team, and create an industry-leading platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Bain Capital Life Sciences
Deal Size : $300.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Chiesi Group
Deal Size : $425.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Moderna will lead discovery efforts, leveraging its leading mRNA technology and delivery platforms along with Chiesi’s expertise in the field of PAH biology.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $25.0 million
September 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Chiesi Group
Deal Size : $425.0 million
Deal Type : Collaboration